Description: Mabion S.A., a biotechnology company, engages in the development of various biotech drugs based on monoclonal antibody technology in Poland. The company develops, produces, and sells medicines for the treatment of neoplastic, autoimmune, metabolic, and neurological diseases. Its products include MabionCD20 and MabionHER2. The company was founded in 2007 and is based in Konstantynów Lódzki, Poland.
Home Page: www.mabion.eu
ul. gen. Mariana Langiewicza 60
Konstantynów Lódzki,
95-050
Poland
Phone:
48 42 207 7890
Officers
| Name | Title |
|---|---|
| Mr. Krzysztof Kaczmarczyk | CEO & Pres of Management Board |
| Dr. Slawomir Jaros EMBA, Eng., Ph.D. | Member of the Management Board & Scientific Director |
| Mr. Grzegorz Grabowicz | Member of Management Board |
| Mr. Adam Pietruszkiewicz | Member of the Management Board |
| Katarzyna Alicja Kutera-Wasiak | Chief Accountant |
Exchange: WAR
Country: PL
Currency: Polish złoty (zł)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 8.191 |
| Price-to-Book MRQ: | 6.2455 |
| Price-to-Sales TTM: | 2.2813 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 244 |